What Happened?
San Diego, CA-based Zavante Therapeutics Appointed Ted Schroeder as Chief Executive Officer
About the Company
Zavante is a clinical-stage biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients.
About the Person
Mr. Schroeder currently serves as President, Chief Executive Officer and a Zavante Director. Previously Mr. Schroeder co-founded Cadence Pharmaceuticals in 2004 and served as president, CEO and member of the board of directors until the company's acquisition by Mallinckrodt Pharmaceuticals in 2014 for $1.4 billion. Under his leadership, Cadence raised in excess of $400 million from private and public investors including completion of a successful IPO, and established a strong hospital-based sales and marketing presence in support of its acute care product. Prior to co-founding Cadence he held several roles at Elan Pharmaceuticals including senior vice president of North American Sales and Marketing and vice president and general manager of the Hospital Products Business Unit, a role he also held at Dura Pharmaceuticals before its acquisition by Elan. Prior to joining Dura, Mr. Schroeder held a number of hospital-relaTed sales and marketing positions with Bristol-Myers Squibb. Mr. Schroeder currently serves on the board of Cidara Therapeutics (Nasdaq:CDTX) and Otonomy, Inc., (Nasdaq: OTIC). Mr. Schroeder previously served on the boards of Hyperion Therapeutics, Incline Therapeutics and Trius Therapeutics until their respective acquisitions. Mr. Schroeder is a member of the Sharp Hospital Foundation board and chair of the BIOCOM board of directors. He holds a bachelor`s degree in management from Rutgers University. In 2014, Mr. Schroeder was named the EY Entrepreneur of the Year for the San Diego region and was named a national EOY finalist that same year. Ted Schroeder is Chief Executive Officer at Zavante Therapeutics. Previously, Ted held various senior HR leadership roles in the industry.
Info Source
Press Release
Short Profile